Skip to main content

Table 1 Demographic, clinical and post-mortem characteristics of the three groups

From: Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study

GroupsControl
n = 32
AD
n = 44
iAD
n = 16
Gender17F:15M28F:16M7F:9M
Age of Death (years, mean ± SD)84 ± 780 ± 679 ± 8
Age of AD onset (years, mean ± SD)n/a70 ± 767 ± 8
Duration of AD (years, mean ± SD)n/a10 ± 312 ± 4
Braak Stage0-II: 29
III-IV: 3
V-VI: 0
0-II: 0
III-IV: 4
V-VI: 40
0-II: 0
III-IV: 1
V-VI: 15
APOE genotypeε4/−3/28 (10.7%)13/38 (34.2%)6/10 (60.0%)
ε4/ε41/28 (3.6%)9/38 (23.7%)3/10 (30.0%)
Post-mortem delay (hours, mean ± SD)42 ± 2342 ± 2622 ± 25
  1. Control neurologically/cognitively normal controls, AD Alzheimer’s disease cases, iAD immunised Alzheimer’s disease cases
  2. F female, M male,
  3. APOE genotyping was not available for all cases
  4. n/a not-applicable, SD standard deviation